About this episode

Professor Sherene Loi discusses the role of tumour-infiltrating lymphocytes as biomarkers in breast cancer with insights from recent publications.

Professor Sherene Loi and the International Immuno-Oncology Biomarker Working Group on tumour-infiltrating lymphocytes as breast cancer biomarkers. Two Articles cover AI and digital pathology scoring methods and a Review examines integrating TILs into radiation oncology trials and clinical practice. The Articles and Review are published in the September 2026 issue of The Lancet Oncology. To read the publications discussed, see: Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00255-X Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00339-6 Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00247-0

More episodes of The Lancet Oncology in conversation with

• 5-year quality of life study of the SUPREMO trial examining chest wall radiotherapy in patients with intermediate-risk breast cancer with Professor Galina Velikova · July 27, 2026 · 12 min

Explore listener stats, chart rankings, contacts and more on the The Lancet Oncology in conversation with podcast page.